Back to GEVA Stock Lookup

GEVA – New Coverage

Jan 8, 2014 07:55 AM Nomura Securities Starts Synageva BioPharma (GEVA) at Buy, $85 PT
Jan 7, 2014 04:15 PM Baird Starts Synageva BioPharma (GEVA) at Outperform
Nov 15, 2013 06:59 AM Buy Synageva (GEVA) Ahead of P-3 data for Sebelipase; Goldman Starts at Buy
Jan 2, 2013 05:53 PM Janney Montgomery Scott Starts Synageva BioPharma (GEVA) at Neutral
Sep 5, 2012 05:21 PM Piper Jaffray Starts Synageva BioPharma (GEVA) at Overweight
Jun 29, 2012 08:26 AM ThinkEquity Starts Synageva BioPharma (GEVA) at Buy
Jun 25, 2012 08:20 AM UPDATE: Canaccord Genuity Starts Synageva BioPharma (GEVA) at Buy; Attractive Orphan Platform
Apr 20, 2012 08:07 AM Morgan Stanley Starts Synageva BioPharma (GEVA) at Overweight
Feb 29, 2012 07:57 AM JPMorgan Starts Synageva BioPharma (GEVA) at Overweight, Sets $50 Price Target
Jan 30, 2012 09:20 AM Cowen Starts Synageva BioPharma (GEVA) at Outperform
Jan 17, 2012 07:19 AM Leerink Swann Starts Synageva BioPharma (GEVA) at Market Perform
Dec 13, 2011 07:04 AM Wedbush Starts Synageva BioPharma (GEVA) at Outperform; Focused on Rare Diseases With Its Golden Eggs

Back to GEVA Stock Lookup